Foresight Diagnostics is a precision medicine company developing a novel liquid biopsy test for the measurement of minimal residual disease (MRD) for aid in patient management that is funded by leading diagnostics VC firms in Silicon Valley. Foresight’s cell-free DNA testing platform was developed in the labs of two prominent professors at Stanford University and is backed by several major peer-reviewed publications. The company has garnered significant partnering interest from multiple pharmaceutical companies in oncology and is poised for rapid growth. Foresight Diagnostics is headquartered in Aurora, Colorado.
Location: United States, Illinois, Aurora
Employees: 11-50
Total raised: $132.75M
Founded date: 2020
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.08.2024 | Series B | $74M | - |
| 27.04.2023 | Series B | $58.75M | Agent Capi... |
Mentions in press and media 8
| Date | Title | Description |
| 02.08.2024 | Foresight Diagnostics: A New Dawn in Cancer Detection | In the world of cancer diagnostics, precision is paramount. Foresight Diagnostics, a Boulder-based company, is at the forefront of this revolution. With its recent Series B financing round, the company has raised a staggering $73.75 million... |
| 01.08.2024 | Business | Foresight Diagnostics completes nearly $74M Series B funding round | Foresight Diagnostics Inc., a Boulder-based cancer diagnostics company that specialized in the development of ultra-sensitive minimal residual disease, or MRD, detection, raised its Series B financing haul to $73.75 million. That total incl... |
| 30.07.2024 | Foresight Diagnostics Expands Series B Financing to $73.75 Million to Advance the Foresight CLARITY™ MRD Platform | BOULDER, Colo., July 30, 2024 (GLOBE NEWSWIRE) -- Foresight Diagnostics, Inc. (“Foresight”), a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease (MRD) detection, today announced the clos... |
| 27.04.2023 | Foresight Diagnostics Nabs $58.75M Series B | AURORA, CO, Foresight Diagnostics announced today that it has closed an oversubscribed Series B financing round of $58.75 million. >> Click here for more funding data on Foresight Diagnostics >> To export Foresight Diagnosti... |
| 27.04.2023 | Foresight Diagnostics Raises $58.75M in Series B Financing | Foresight Diagnostics, an Aurora, CO-based developer of cancer detection tests, raised $58.75M in Series B funding. The round was led by Foresite Capital, with participation by Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent ... |
| - | Foresight Diagnostics | “Foresight Diagnostics make the world’s most sensitive ctDNA/cfDNA liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.” |
| - | Foresight Diagnostics | “The world’s most sensitive liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.” |
| - | Healthcare hires of note | These job announcements are intended to highlight some of the hiring news over the past month and are not intended to be comprehensive. If you’d like to share job listings or announcements on our website, please contact Winnie Liu at this e... |